AR038549A1 - Derivados de aminociclohexano heteroarilsustituidos - Google Patents

Derivados de aminociclohexano heteroarilsustituidos

Info

Publication number
AR038549A1
AR038549A1 ARP020104958A ARP020104958A AR038549A1 AR 038549 A1 AR038549 A1 AR 038549A1 AR P020104958 A ARP020104958 A AR P020104958A AR P020104958 A ARP020104958 A AR P020104958A AR 038549 A1 AR038549 A1 AR 038549A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
alkoxy
cycloalkyl
hydrogen
alkyl
Prior art date
Application number
ARP020104958A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR038549A1 publication Critical patent/AR038549A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos de la fórmula (1), y su manufactura y uso como medicamentos, en los cuales A1, A2, A3, A4, A5, A6, U, V, m, n y o son tal como se han definido en la descripción y reivindicaciones, y las sales farmacéuticamente aceptables de los mismos. Los compuestos son útiles para el tratamiento y/o profilaxis de enfermedades que están asociadas con 2,3-oxidoescualeno-lanoesterol ciclasa tal como hipercolesterolemia, hiperlipemia, arterioesclerosis, enfermedades vasculares, micosis, infecciones parasitarias, cálculos vesicales, tumores y/o desordenes hiperproliferativos y para el tratamiento y/o la alteración de la tolerancia a la glucosa y diabetes. Reivindicación 1: Un compuesto de la fórmula (1), en la cual: U es O ó un par aislado; V es un enlace simple, O, S, -CH=CH-CH2-O-, -CH=CH-, o -CsC-, m y n independientemente uno del otro son 0 a 7 y m+n es 0 a 7, con la condición de que m no es 0 si V es O ó S, o es 0 a 2; A1 es hidrógeno, alquilo inferior, hidroxi-alquilo inferior, o alquenilo inferior, A2 es alquilo inferior, cicloalquilo, cicloalquilo-alquilo inferior, o alquenilo inferior opcionalmente sustituido con R1, o A1 y A2 están unidos entre sí para formar un anillo y -A1-A2- es alquileno inferior o alquenileno inferior opcionalmente sustituido con R1 en el cual un grupo -CH2- de -A1-A2- puede estar opcionalmente reemplazado con NR2, S u O; A3 y A4 independientemente uno del otro son hidrógeno o alquilo inferior, o A3 y A4 están unidos entre sí para formar un anillo conjuntamente con el átomo de carbono al cual están unidos y -A3-A4- es -(CH2)2-5-; A5 es hidrógeno, alquilo inferior, o alquenilo inferior, A6 es piridinilo, piridazinilo, pirimidinilo o pirazinilo, opcionalmente sustituido con 1 ó 2 sustituyentes independientemente seleccionados del grupo que consiste en alquilo inferior, alquilo inferior-cicloalquilo, tio-alcoxi inferior, cicloalquilo, carbamoilo, carboxi, carboxi-alquilo inferior, ciano, amino, mono- y dialquilamino, alcoxi inferior, alcoxi inferior-alquilo inferior, alcoxi inferior-carbonilo, alcoxi inferior-carbonilo-alquilo inferior, alquenilo inferior, alquinilo inferior, arilo, arilo-alquilo inferior, ariloxi, halógeno, heteroarilo, heterocíclico, heterociclil-alquilo inferior y trifluormetilo; R1 es hidroxi, hidroxi-alquilo inferior, alcoxi inferior, alcoxi carbonilo inferior, halógeno, CN, N(R3, R4) o tio-alcoxi-inferior, R2, R3 y R4 independientemente uno del otro son hidrógeno o alquilo inferior, y sus sales farmacéuticamente aceptables con la condición de que el compuesto de fórmula (1) no sea trans-[4-(2-Dipropilamino-etil)-ciclohexil]-pirimidin-2-il-amina.
ARP020104958A 2001-12-20 2002-12-18 Derivados de aminociclohexano heteroarilsustituidos AR038549A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01130284 2001-12-20

Publications (1)

Publication Number Publication Date
AR038549A1 true AR038549A1 (es) 2005-01-19

Family

ID=8179606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104958A AR038549A1 (es) 2001-12-20 2002-12-18 Derivados de aminociclohexano heteroarilsustituidos

Country Status (16)

Country Link
US (1) US7012077B2 (es)
EP (1) EP1458683B1 (es)
JP (1) JP4316384B2 (es)
KR (1) KR20040075905A (es)
CN (1) CN1296357C (es)
AR (1) AR038549A1 (es)
AT (1) ATE346045T1 (es)
AU (1) AU2002366732B2 (es)
BR (1) BR0215257A (es)
CA (1) CA2469380C (es)
DE (1) DE60216319T2 (es)
ES (1) ES2275939T3 (es)
MX (1) MXPA04005907A (es)
PL (1) PL370713A1 (es)
RU (1) RU2286987C2 (es)
WO (1) WO2003053933A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293744B2 (en) * 2000-08-16 2007-05-10 F. Hoffmann-La Roche Ag Novel aminocyclohexane derivatives
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
CN101475528A (zh) * 2003-03-31 2009-07-08 大正制药株式会社 新的喹啉、四氢喹唑啉和嘧啶衍生物以及与其应用有关的治疗方法
CA2545048A1 (en) * 2003-11-20 2005-06-02 Warner-Lambert Company Llc Androgen receptor modulators
ITMI20110666A1 (it) * 2011-04-19 2012-10-20 Dipharma Francis Srl Procedimento per la preparazione di (r) ed (s) pramipexolo e suoi intermedi
CN104936953B (zh) 2013-01-23 2017-03-08 阿斯利康(瑞典)有限公司 化合物
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
TWI751271B (zh) 2017-01-23 2022-01-01 美商凱登製藥公司 鉀離子通道調節子
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO122123B (es) 1966-03-25 1971-05-24 Miles Lab
US3592824A (en) 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
DE4239151A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
CA2190699A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
US6964974B2 (en) 2000-09-08 2005-11-15 Hoffmann-La Roche Inc. 2,3-oxidosqualene-lanosterol cyclase inhibitors
CN1261429C (zh) 2000-11-02 2006-06-28 弗·哈夫曼-拉罗切有限公司 降胆固醇的苯并「b」噻吩和苯并「d」异噻唑

Also Published As

Publication number Publication date
RU2004122480A (ru) 2005-08-10
JP4316384B2 (ja) 2009-08-19
EP1458683B1 (en) 2006-11-22
EP1458683A1 (en) 2004-09-22
AU2002366732A1 (en) 2003-07-09
AU2002366732B2 (en) 2006-11-02
US7012077B2 (en) 2006-03-14
RU2286987C2 (ru) 2006-11-10
CA2469380A1 (en) 2003-07-03
ES2275939T3 (es) 2007-06-16
US20030186984A1 (en) 2003-10-02
WO2003053933A1 (en) 2003-07-03
DE60216319T2 (de) 2007-05-31
JP2005517667A (ja) 2005-06-16
ATE346045T1 (de) 2006-12-15
CA2469380C (en) 2010-01-26
BR0215257A (pt) 2004-12-07
MXPA04005907A (es) 2004-09-13
KR20040075905A (ko) 2004-08-30
CN1610669A (zh) 2005-04-27
PL370713A1 (en) 2005-05-30
DE60216319D1 (en) 2007-01-04
CN1296357C (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
ES2639064T3 (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
UY27666A1 (es) Nuevos derivados de piridina y quinolina
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
MY137156A (en) Dual nk1/nk3 derivatives
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
AR044796A1 (es) Derivados de pirido (2, 1-a) isoquinolina como inhibidores de la dpp iv
SE0104334D0 (sv) Therapeutic agents
ATE427926T1 (de) Cycloalkylaminderivate
UY27665A1 (es) Nuevos derivados de piridina y pirimidina
AU2018326721B2 (en) Compounds and compositions for IRE1 inhibition
TW200621762A (en) Novel compounds
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
WO2004018475A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
NO20072389L (no) Substituerte benzokinolizinderivater
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
AR038549A1 (es) Derivados de aminociclohexano heteroarilsustituidos
PE20010478A1 (es) Usos y composiciones de inhibidores de fosfodiesterasa tipo 5 del 3`,5'-guanosinmonofosfato ciclico para el tratamiento de enfermedades y condiciones del ojo
NO20055176L (no) Benzotiazolderivater og anvendelse derav i behandling av sykdommer vedrorende adenosin A2A-resepor
AU2004203910A8 (en) Use of 2-amino-2H-quinazoline derivatives for producing therapeutic agents
CA2388470A1 (en) Use of carbonylamino derivatives against cns disorders
UY27559A1 (es) Derivados del benzotiazol.
UY27074A1 (es) Derivados de aminotriazolopiridina
AR032623A1 (es) Compuestos derivados de anilina, piridinamina y pirimidinamina, su uso, un procedimiento para su elaboracion y composiciones farmaceuticas que los comprenden
AR052553A1 (es) Derivados de benzoil -tetrahidropiridina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal